Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

By J. Moses, M. Leon, J. Popma, P. Fitzgerald, David R. Holmes III, C. O'shaughnessy, R. Caputo, D. Kereiakes, David O. Williams, P. Teirstein and 2 more. New England Journal of Medicine, 2003

4,504 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/b51e6bf2f9dc38f76c55ea2caa185b11833901ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Chiu
2. Robert M. Califf

In Surgery

1. Shu Chien
2. Robert M. Califf
3. J. Blenis
4. J. Chiu

Citations in the corpus

• Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry (2004, background): “The primary outcome was the occurrence of major adverse cardiac events, defined as (1) death, (2) nonfatal myocardial infarction, or (3) target vessel revascularization.”
• Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study (2012, neutral): “거해 이루어졌고, 주로 초기 1세대 약물용출스텐트 관 련 data를 근거로 정해졌다.(1) 그러나 실제로 이를 뒷받침”